Will one size of anticoagulant dosage fit all?

Drug Development Research

Volumn 74, Issue 7, 2013, Pages 406-412

  Bloemen, Saartje ^a   De Laat, Marieke ^a   De Laat, Bas ^a   Hemker, Hendrik Coenraad ^a   Al Dieri, Raed ^a,b  

^a Synapse BV   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

anticoagulants; monitoring; thrombin generation

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84886396508     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21097     Document Type: Review

References (56)

1. Adams M,. 2009. Assessment of thrombin generation: useful or hype? Semin Thromb Hemost 35: 104-110.
2. Al Dieri R, Alban S, Beguin S, Hemker HC,. 2004. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2: 1395-1401.
3. Al Dieri R, Alban S, Béguin S, Hemker HC,. 2006. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4: 83-89.
4. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Béguin S, Hemker HC,. 2002. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 88: 576-582.
5. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E,. 2004. The Pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 204S-233S.
6. Baglin T,. 2010. Unraveling the thrombophilia paradox: from hypercoagulability to the prothrombotic state. J Thromb Haemost 8: 228-233.
7. Bloemen S, Hemker HC, Al Dieri R,. 2013. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 98: 549-554.
8. Bosch Y, Al Dieri R, ten Cate H, Nelemans P, Bloemen S, Hemker HC, Weerwind PW, Maessen JG, Mochtar B,. 2013. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg 8: 154.
9. Boström SL, Hansson GF, Kjaer M, Sarich TC,. 2003. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 14: 457-462.
10. Bounameaux H, Reber G,. 2010. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost 8: 627-630.
11. Brocal I, Marco P, Lucas J, Verdu J, Tarin F,. 2009. Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists. Thromb Haemost 101: 594-595.
12. Coakley M, Hall JE, Evans C, Duff E, Billing V, Yang L, McPherson D, Stephens E, Macartney N, Wilkes AR, et al. 2011. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 9: 282-292.
13. de Laat B, van Os G, Ninivaggi M, Agar C, de Groot P, Hemker HC, Lindhout T, Meijers J,. 2011. Anti-domain I antibodies have a prothrombotic character on coagulation by inhibiting the anticoagulant effect of beta2GPI. Thromb Haemost 9 (S2): 290-291.
14. Delavenne X, Zufferey P, Baylot D, Nguyen P, Borg JY, Fontenay M, Deygas B, Mismetti P, Laporte S,. 2010. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. Thromb Haemost 104: 252-260.
15. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJM, Leyte A,. 2013. In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban. J Thromb Haemost 11: 1111-1118.
16. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM,. 2012a. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 107: 985-997.
17. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM,. 2012b. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130: 956-966.
18. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. 2011. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrat: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124: 1573-1579.
19. Eikelboom JW, Hirsh J,. 2006. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 96: 547-552.
20. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckman H, Muehlhofer E, Misselwitz F, et al. 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358: 2765-2775.
21. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, et al. 2007a. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee-replacement: the RE-MODEL randomized trial. J Thromb Haemost 5: 2178-2185.
22. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, et al. 2007b. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370: 949-956. [Erratum, Lancet 2007; 370:2004.].
23. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, et al. 2006. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27: 1979-2030.
24. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M,. 2008. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 100: 350-355.
25. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW,. 2008. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S-453S.
26. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG,. 2004. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti- thrombotic and Thrombolytic Therapy. Chest 126: 338S-400S.
27. Goldhaber SZ,. 1992. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol 19: 246-247.
28. Granger CB, Armaganijan LV,. 2012. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 125: 159-164.
29. Greaves M,. 2002. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 87: 163-164.
30. Gustafsson D, Elg M,. 2003. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 109 (Suppl 1): S9-15.
31. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T,. 2010. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with Calibrated Automated Thrombography. Thromb Res 127: 29-34.
32. Hart RG, Benavente O, McBride R, Pearce LA,. 1999. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492-501.
33. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S,. 2002. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32: 249-253.
34. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE,. 2001. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64S-94S.
35. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA,. 2006. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296: 397-402.
36. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S,. 2007. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115: 2689-2696.
37. King CS, Holley AB, Moores LK,. 2013. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor xa inhibitors. Chest 143: 1106-1116.
38. Kyrle PA, Mannhalter C, Beguin S, Stümpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, et al. 1998. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18: 1287-1291.
39. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel RJ, Misselwitz F, Turpie AGG,. 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358: 2776-2786.
40. Levi M, Eerenberg E, Kamphuisen PW,. 2011. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9: 1705-1712.
41. Lip GYH, Tse HF, Lane DA,. 2012. Atrial fibrillation. Lancet 379: 648-661.
42. Loeliger EA, Hensen A, Kroes F, van Dijk LM, Fekkes N, de Jonge H, Hemker HC,. 1967. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 182: 549-566.
43. Mismetti P, Laporte S,. 2010. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 8: 621-626.
44. Molenaar PJ, Dinkelaar J, Leyte A,. 2012. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 50: 1799-1807.
45. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI,. 2008. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100: 453-461.
46. Neri Serneri GG, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L, Rostagno C, Tamburini C, Carnovali M, Magnani B,. 1995. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 345: 1201-1204.
47. Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A,. 1987. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1: 937-942.
48. Poli D, Antonucci E, Marcucci R, Fatini C, Alterini B, Mannini L, Falciani M, Abbate R, Gensini GF, Prisco D,. 2007. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 121: 347-352.
49. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS,. 1996. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/ human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 98: 863-874.
50. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, Dogne JM,. 2009. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 59: 160-166.
51. Rothwell PM,. 1995. Can overall results of clinical trials be applied to all patients? Lancet 345: 1616-1619.
52. Schulman S, Crowther MA,. 2012. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switck. Blood 119: 3016-3023.
53. Tripodi A, van den Besselaar A,. 2009. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 35: 34-41.
54. van den Besselaar A,. 1989. Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go? Ric Clin Lab 19: 371-377.
55. van Veen JJ, Gatt A, Makris M,. 2008. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 142: 889-903.
56. Weitz JI, Gross PL,. 2012. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program 2012: 536-540.